Inventor · disambiguated record
Andrew P. Crew
Also filed as: CREW ANDREW · CREW ANDREW P · CREW ANDREW PHILLIP
54 granted patents·36 pending applications·326 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
90 records- 0198US11236051B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Feb 1, 2022·9 cites·3 claims
- 0298US11104666B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Aug 31, 2021·18 cites·15 claims
- 0398US10899742B1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Jan 26, 2021·18 cites·25 claims
- 0498US10844021B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Nov 24, 2020·13 cites·25 claims
- 0598US10647698B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS INC·Filed 2017·Granted May 12, 2020·31 cites·6 claims
- 0698US10584101B2Compounds and methods for the targeted degradation of androgen receptorARVINAS INC·Filed 2017·Granted Mar 10, 2020·35 cites·6 claims
- 0797US11952347B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2021·Granted Apr 9, 2024·3 cites·7 claims
- 0897US10730870B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS INC·Filed 2016·Granted Aug 4, 2020·25 cites·22 claims
- 0996US10772962B2Compounds and methods for the targeted degradation of bromodomain-containing proteinsARVINAS INC·Filed 2016·Granted Sep 15, 2020·15 cites·23 claims
- 1095US10723717B2Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptidesARVINAS INC·Filed 2017·Granted Jul 28, 2020·16 cites·44 claims
- 1192US11964945B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Apr 23, 2024·2 cites·26 claims
- 1292US11173211B2Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptidesARVINAS OPERATIONS INC·Filed 2019·Granted Nov 16, 2021·6 cites·25 claims
- 1392US11065231B2Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptidesARVINAS OPERATIONS INC·Filed 2018·Granted Jul 20, 2021·16 cites·24 claims
- 1492US10071164B2Estrogen-related receptor alpha based protac compounds and associated methods of useUNIV YALE·Filed 2015·Granted Sep 11, 2018·8 cites·9 claims
- 1592US7485658B2N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitorsOSI PHARM INC·Filed 2004·Granted Feb 3, 2009·39 cites·5 claims
- 1691US12036209B2Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptidesARVINAS OPERATIONS INC·Filed 2021·Granted Jul 16, 2024·2 cites·3 claims
- 1791US11384063B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2020·Granted Jul 12, 2022·2 cites·8 claims
- 1890US2025320195A1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1989US11191741B2Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptideARVINAS OPERATIONS INC·Filed 2017·Granted Dec 7, 2021·3 cites·13 claims
- 2089US11161841B2Modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2019·Granted Nov 2, 2021·3 cites·22 claims
- 2189US2025034096A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 2288US11352351B2Compounds and methods for the targeted degradation of androgen receptorARVINAS INC·Filed 2016·Granted Jun 7, 2022·4 cites·16 claims
- 2387US11912699B2Tau-protein targeting compounds and associatedARVINAS OPERATIONS INC·Filed 2020·Granted Feb 27, 2024·2 cites·21 claims
- 2487US10604506B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS INC·Filed 2018·Granted Mar 31, 2020·3 cites·20 claims
- 2586US10994015B2EGFR proteolysis targeting chimeric molecules and associated methods of useARVINAS OPERATIONS INC·Filed 2017·Granted May 4, 2021·3 cites·25 claims
- 2685US12427144B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2023·Granted Sep 30, 2025·0 cites·16 claims
- 2785US11707452B2Modulators of alpha-synuclein proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2019·Granted Jul 25, 2023·2 cites·19 claims
- 2885US11427548B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Aug 30, 2022·2 cites·15 claims
- 2985US2025228944A1Compounds and methods for the targeted degradation of bromodomain-containing proteinsARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 3084US11512083B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2020·Granted Nov 29, 2022·1 cites·17 claims
- 3183US11458123B2Tau-protein targeting PROTACs and associated methods of useARVINAS INC·Filed 2017·Granted Oct 4, 2022·2 cites·16 claims
- 3282US7101893B2(2-Carboxamido)(3-amino)thiophene compoundsOSI PHARM INC·Filed 2005·Granted Sep 5, 2006·4 cites·2 claims
- 3382US6949563B2(2-carboxamido)(3-amino)thiophene compoundsWYNNE GRAHAM MICHAEL·Filed 2004·Granted Sep 27, 2005·19 cites·16 claims
- 3482US2025223265A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 3581US10865202B2Indole derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2019·Granted Dec 15, 2020·1 cites·20 claims
- 3680US12171831B2Compounds and methods for the targeted degradation of bromodomain- containing proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Dec 24, 2024·0 cites·14 claims
- 3779US12441708B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Oct 14, 2025·0 cites·20 claims
- 3879US12239711B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Mar 4, 2025·0 cites·1 claims
- 3979US2024382599A1Egfr proteolysis targeting chimeric molecules and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 4078US12264157B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Apr 1, 2025·0 cites·24 claims
- 4178US12172981B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2021·Granted Dec 24, 2024·0 cites·18 claims
- 4278US10806737B2Compounds and methods for the targeted degradation of fetal liver kinase polypeptidesARVINAS OPERATIONS INC·Filed 2017·Granted Oct 20, 2020·2 cites·23 claims
- 4378US2025313547A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 4477US2025360219A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
- 4576US2024059686A1Compounds and methods for the targeted degradation of the androgen receptorARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
- 4674US7521448B2N-substituted benzimidazolyl c-Kit inhibitorsOSI PHARM INC·Filed 2004·Granted Apr 21, 2009·9 cites·6 claims
- 4774US7439256B2(Arylamidoaryl) cyanoguanidine compoundsCASTELHANO ARLINDO·Filed 2005·Granted Oct 21, 2008·5 cites·8 claims
- 4874US2024299366A1Imide-based modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Application pending·0 cites
- 4974US2021040044A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Application pending·0 cites
- 5073US12275716B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2022·Granted Apr 15, 2025·0 cites·16 claims
Showing the top 50 of 90 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →